How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/congenital-heart-defect-requiring-open-patent-ductus-arteriosus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Congenital Heart Defect Requiring Open Patent Ductus Arteriosus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Congenital Heart Defect Requiring Open Patent Ductus Arteriosus (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Congenital Heart Defect Requiring Open Patent Ductus Arteriosus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Caverject	ALPROSTADIL	Pfizer	Prostaglandin Analog [EPC]	Prostaglandin E2 receptor EP3 subtype		1981-01-01
Prostavasin	Prostavasin	Hannover Medical School		Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Hannover Medical School · 1 drug in Congenital Heart Defect Requiring Open Patent Ductus Arteriosus
Pfizer · 1 drug in Congenital Heart Defect Requiring Open Patent Ductus Arteriosus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital Heart Defect Requiring Open Patent Ductus Arteriosus:

Cite this brief

Drug Landscape (2026). Congenital Heart Defect Requiring Open Patent Ductus Arteriosus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-heart-defect-requiring-open-patent-ductus-arteriosus. Accessed 2026-06-10.

Congenital Heart Defect Requiring Open Patent Ductus Arteriosus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing